Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
Ruben J ColmanStephanie A VuijkRon A A MathôtJohan Van LimbergenMaria M E JongsmaMarco W J SchreursPhillip Paul MinarLissy de RidderGeert R A M D'HaensPublished in: Inflammatory bowel diseases (2024)
This study suggests that there are no PK differences (TLs and CL) between combo and mono therapy in pediatric CD patients who started IFX.